Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation.
about
Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behaviorProperties, production, and applications of camelid single-domain antibody fragmentsStructure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodiesAlpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs).Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library.Differential recognition of vascular and parenchymal beta amyloid deposition.Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from Porphyromonas gingivalis.Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein.Adenoviral targeting using genetically incorporated camelid single variable domains.Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.Kinetics of PKCε activating and inhibiting llama single chain antibodies and their effect on PKCε translocation in HeLa cellsConstruction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications.Analysis and modeling of the variable region of camelid single-domain antibodies.Selection and characterization of llama single domain antibodies against N-terminal huntingtinDevelopment of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis.A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.Single domain antibodies for the knockdown of cytosolic and nuclear proteins.Affinity reagent resources for human proteome detection: initiatives and perspectives.Survey of the year 2006 commercial optical biosensor literature.Antibody technology in proteomics.High-resolution melting analysis (HRMA): more than just sequence variant screening.Nanobodies®: proficient tools in diagnostics.Biotechnological applications of recombinant single-domain antibody fragments.Arginine methylation of the nuclear poly(a) binding protein weakens the interaction with its nuclear import receptor, transportin.Antibody Fragments as Probe in Biosensor Development.Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine functionEndogenous DKK1 and FRZB Regulate Chondrogenesis and Hypertrophy in Three-Dimensional Cultures of Human Chondrocytes and Human Mesenchymal Stem Cells.Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma.Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.PTAA and B10: new approaches to amyloid detection in tissue-evaluation of amyloid detection in tissue with a conjugated polyelectrolyte and a fibril-specific antibody fragment.
P2860
Q24314981-AE07D182-04F6-45A7-B2F1-A8F4D76B0006Q24676749-5892D8D0-9F09-4F16-B59E-9766E9AB7505Q27681380-55B45BD4-6C9C-438D-B632-3FCCE60D4CB5Q33287667-9C6D0C1F-3EAF-4990-8C33-DC3B583B926EQ33406065-B3EB0748-66B7-4423-AF4F-5EC05A58209BQ33518955-5E2857BF-384F-438D-8751-B5CEF7719FDCQ33899359-B4394F63-8D46-4145-B354-F906638AF0A2Q34110625-D5406CE3-8E26-4DFB-8194-A90ABD9284D7Q34149036-9E4953AF-5FF4-4226-8436-D9E158329F35Q34206171-6E736C74-ABA7-4B2B-94A2-D95F2060C4A3Q34247420-F7EAD077-D0F1-4477-942B-444292F4BE99Q34728036-6423E51B-9B59-4A6C-9DBC-6C190E217275Q34995448-A1458668-9DEE-415D-9249-EAE27A2B0BB0Q35123206-33A8F869-B938-40D4-8676-1A0D71C80B32Q35153910-9A0B9254-1A8F-4186-958B-C02F422692A5Q35173029-E8FBD741-0BEF-4871-84A6-2322EB93447AQ35683767-66C96F99-E2FC-457D-90E1-6FF9BB7B32A9Q36300378-B0942282-431E-46A8-8172-4469CBC6B053Q36886056-D99E472E-6B92-44A8-AF4F-492091C23160Q37030018-A0F620A3-2EA3-437B-9570-68D5FE0A1286Q37202448-B26203DB-9E20-4A34-BD67-3F6BF4536AD6Q37471717-425B3DAD-B318-41E8-B92A-A4A970AA50CBQ37789032-23452660-A275-47CB-90CC-C761A3AD268EQ37887077-B51AAEE1-A6F3-488F-B3BA-1D8AAC7315FAQ38675325-25CC2E01-5465-43F2-BB9E-5144AFFD7FE4Q39016494-DC1755CC-9458-44E0-B2F6-6CC423B0265DQ41861205-CBF9F8E9-0A86-4F5A-BDE8-82F10C061369Q41984107-0757958D-22B4-4493-98EB-80ED9F761B54Q42622617-7EC022BB-AD79-4E5C-8503-406378308131Q42697422-5078EB79-0A0D-435D-B952-46D9E8D0F026Q46981111-9E657963-0C2B-47F0-9039-677816496A52
P2860
Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Reliable and controllable anti ...... braries for target validation.
@ast
Reliable and controllable anti ...... braries for target validation.
@en
type
label
Reliable and controllable anti ...... braries for target validation.
@ast
Reliable and controllable anti ...... braries for target validation.
@en
prefLabel
Reliable and controllable anti ...... braries for target validation.
@ast
Reliable and controllable anti ...... braries for target validation.
@en
P2093
P1476
Reliable and controllable anti ...... braries for target validation.
@en
P2093
Arie J Verkleij
Arjan J Groot
C Theo Verrips
Hans J de Haard
Johan T den Dunnen
Jord C Stam
Peter Verheesen
Rune R Frants
P304
P356
10.1016/J.BBAPAP.2006.05.011
P407
P577
2006-06-10T00:00:00Z